Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Drugs · 2024-02 · 84 (2) · 165-178
DOI: 10.1007/s40265-024-01995-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs, online erschienen am 25.01.2024. Verfasst von Willemijn A M Schonck und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Anticholesteremic Agents. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Increased plasma levels of low-density lipoprotein cholesterol (LDL-C) are causally associated with atherosclerotic cardiovascular disease (ASCVD), and statins that lower LDL-C have been the cornerstone of ASCVD prevention for decades. However, guideline-recommended LDL-C targets are not achieved in about 60% of statin users. Proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeted therapy effectively lowers LDL-C levels and has been shown to reduce ASCVD risk. A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence of side effects in the short term. In this review, we present and discuss the current clinical and scientific evidence pertaining to the long-term efficacy and tolerability of PCSK9-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
- Global Chief Medical Office, Novo Nordisk, Copenhagen, Denmark.
- Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.f.reeskamp@amsterdamumc.nl.
Zitieren
APA
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024). Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs, 84(2), 165-178. https://doi.org/10.1007/s40265-024-01995-9
Vancouver
Schonck WAM, Stroes ESG, Hovingh GK, Reeskamp LF. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs. 2024;84(2):165-178. doi:10.1007/s40265-024-01995-9
BibTeX
@article{Schonck2024,
author = {Schonck, Willemijn A M and Stroes, Erik S G and Hovingh, G Kees and Reeskamp, Laurens F},
title = {Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature},
journal = {Drugs},
year = {2024},
volume = {84},
number = {2},
pages = {165--178},
doi = {10.1007/s40265-024-01995-9}
}
EUVIMED